Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Sarcoma 5Neoplasms 5Rhabdomyosarcoma 4Prostatic Neoplasms 4Osteosarcoma 3Breast Neoplasms 3Sarcoma, Synovial 2Sarcoma, Ewing 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplasm Metastasis 2Lung Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Adrenocortical Carcinoma 2Wilms Tumor 1Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Retinoblastoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neuroblastoma 1Mesothelioma, Malignant 1Liver Neoplasms 1Liposarcoma 1

Interventions

Carboplatin 23Cisplatin 19pembrolizumab 14Paclitaxel 13Gemcitabine 12Pemetrexed 11130-nm albumin-bound paclitaxel 9Everolimus 8Cetuximab 8Fluorouracil 7Docetaxel 6Axitinib 6Albumin-Bound Paclitaxel 6osimertinib 5durvalumab 5Sunitinib 5Radiotherapy 5Nivolumab 5Erlotinib Hydrochloride 5Cyclophosphamide 5Sorafenib 4Radiation 4Irinotecan 4Ipilimumab 4vosaroxin 3Radiotherapy, Intensity-Modulated 3Octreotide 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3trifluridine tipiracil drug combination 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma × cixutumumab × Clear all
NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡